STOCK TITAN

[6-K] Dr. Reddy's Laboratories Limited American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Form 4 snapshot: On 07/21/2025 Columbus McKinnon Corp. (CMCO) director Christopher J. Stephens reported the award of 8,553 common shares under the company’s Second Amended & Restated 2016 Long-Term Incentive Plan. The transaction is coded “A” (acquisition) at a reporting price of $15.21 per share, implying a notional value of roughly $130 k.

The grant lifts Stephens’ direct holdings to 19,567 shares, an increase of about 78% versus his prior position. No derivative securities were exercised or disposed of, and there were no sales or other insider dispositions disclosed.

While equity grants do not involve an out-of-pocket purchase, the filing still modestly strengthens insider equity alignment and sends a generally constructive governance signal. The overall dollar amount is immaterial to CMCO’s capitalization, so market impact should be limited.

Riepilogo del Modulo 4: Il 21/07/2025, il direttore di Columbus McKinnon Corp. (CMCO), Christopher J. Stephens, ha comunicato la concessione di 8.553 azioni ordinarie nell'ambito del Piano di Incentivazione a Lungo Termine 2016, Seconda Versione Modificata e Riformulata della società. L'operazione è classificata come “A” (acquisizione) a un prezzo di riferimento di 15,21 $ per azione, corrispondente a un valore nominale di circa 130.000 $.

La concessione porta la partecipazione diretta di Stephens a 19.567 azioni, un incremento di circa il 78% rispetto alla sua posizione precedente. Non sono stati esercitati o ceduti strumenti derivati, né sono state segnalate vendite o altre cessioni da parte di insider.

Pur non richiedendo un esborso diretto, la concessione rafforza modestamente l’allineamento azionario degli insider e invia un segnale generalmente positivo in termini di governance. L’importo complessivo è irrilevante rispetto alla capitalizzazione di CMCO, quindi si prevede un impatto limitato sul mercato.

Resumen del Formulario 4: El 21/07/2025, el director de Columbus McKinnon Corp. (CMCO), Christopher J. Stephens, reportó la adjudicación de 8,553 acciones ordinarias bajo el Plan de Incentivos a Largo Plazo Enmendado y Reformulado de 2016 de la compañía. La transacción está codificada como “A” (adquisición) a un precio de reporte de 15,21 $ por acción, lo que implica un valor nominal aproximado de 130.000 $.

La concesión eleva la participación directa de Stephens a 19.567 acciones, un aumento de alrededor del 78% respecto a su posición anterior. No se ejercieron ni se dispusieron valores derivados, y no se divulgaron ventas u otras disposiciones por parte de insiders.

Aunque las concesiones de acciones no implican una compra directa, la presentación fortalece modestamente la alineación accionarial de los insiders y envía una señal generalmente constructiva de gobernanza. El monto total es insignificante para la capitalización de CMCO, por lo que se espera que el impacto en el mercado sea limitado.

Form 4 요약: 2025년 7월 21일, Columbus McKinnon Corp.(CMCO) 이사인 Christopher J. Stephens가 회사의 2016년 제2차 수정 및 재작성 장기 인센티브 계획에 따라 8,553주 보통주 수여를 보고했습니다. 거래는 “A”(취득)로 분류되었으며, 보고 가격은 주당 15.21달러로, 명목 가치는 약 13만 달러에 해당합니다.

이번 수여로 Stephens의 직접 보유 주식이 19,567주로 증가했으며, 이전 보유량 대비 약 78% 증가한 수치입니다. 파생 증권의 행사나 처분은 없었고, 매도나 기타 내부자 처분도 보고되지 않았습니다.

주식 수여는 현금 지출을 수반하지 않지만, 이번 신고는 내부자의 지분 정렬을 다소 강화하며 대체로 긍정적인 거버넌스 신호를 보냅니다. 전체 금액은 CMCO 자본금에 비해 미미하여 시장 영향은 제한적일 것으로 예상됩니다.

Résumé du formulaire 4 : Le 21/07/2025, Christopher J. Stephens, administrateur de Columbus McKinnon Corp. (CMCO), a déclaré l’attribution de 8 553 actions ordinaires dans le cadre du Plan d’incitation à long terme modifié et reformulé de 2016 de la société. La transaction est codée « A » (acquisition) à un prix déclaré de 15,21 $ par action, ce qui implique une valeur notionnelle d’environ 130 000 $.

Cette attribution porte la détention directe de Stephens à 19 567 actions, soit une augmentation d’environ 78 % par rapport à sa position précédente. Aucun titre dérivé n’a été exercé ou cédé, et aucune vente ou autre cession d’initié n’a été divulguée.

Bien que les attributions d’actions ne nécessitent pas d’achat direct, ce dépôt renforce modestement l’alignement des intérêts des initiés et envoie un signal de gouvernance généralement positif. Le montant total est négligeable par rapport à la capitalisation de CMCO, donc l’impact sur le marché devrait être limité.

Formular 4 Zusammenfassung: Am 21.07.2025 meldete Christopher J. Stephens, Direktor von Columbus McKinnon Corp. (CMCO), die Zuteilung von 8.553 Stammaktien im Rahmen des Zweiten Geänderten und Neuformulierten Langfristigen Anreizplans 2016 des Unternehmens. Die Transaktion ist mit „A“ (Erwerb) codiert und erfolgte zu einem Berichtspreis von 15,21 $ pro Aktie, was einem nominellen Wert von etwa 130.000 $ entspricht.

Die Zuteilung erhöht Stephens’ direkten Bestand auf 19.567 Aktien, eine Steigerung von etwa 78 % gegenüber seiner vorherigen Position. Es wurden keine Derivate ausgeübt oder veräußert, und es gab keine Verkäufe oder sonstigen Insider-Transaktionen.

Obwohl Aktienzuteilungen keinen direkten Kauf erfordern, stärkt die Meldung die Insider-Aktienausrichtung leicht und sendet ein insgesamt positives Governance-Signal. Der Gesamtbetrag ist im Verhältnis zur Kapitalisierung von CMCO unerheblich, daher sollte der Markteinfluss begrenzt sein.

Positive
  • Director ownership rises 78%, signaling stronger alignment with shareholders
  • No insider sales or derivative disposals, reducing negative governance signals
Negative
  • None.

Insights

TL;DR: Director received stock grant; increases stake, modest positive sentiment.

The award adds roughly $130 k of CMCO equity to Stephens’ account, pushing his direct stake to nearly 20 k shares. Insider accumulation—even via compensation—tends to be viewed favorably, as it tightens shareholder-director alignment. However, because this is a scheduled LTIP grant rather than an open-market buy, the informational value is weaker and should not materially alter valuation models. No negative indicators such as option exercises followed by sales are present.

TL;DR: Routine LTIP grant; governance alignment intact, risk neutral.

The filing confirms compliance with CMCO’s 2016 LTIP and shows continued use of equity-based compensation for directors. The absence of derivative positions or rapid disposals lowers governance risk. While the stake increase is small relative to board holdings overall, it maintains best-practice alignment. I classify the event as not impactful to control structure but mildly positive for incentive alignment.

Riepilogo del Modulo 4: Il 21/07/2025, il direttore di Columbus McKinnon Corp. (CMCO), Christopher J. Stephens, ha comunicato la concessione di 8.553 azioni ordinarie nell'ambito del Piano di Incentivazione a Lungo Termine 2016, Seconda Versione Modificata e Riformulata della società. L'operazione è classificata come “A” (acquisizione) a un prezzo di riferimento di 15,21 $ per azione, corrispondente a un valore nominale di circa 130.000 $.

La concessione porta la partecipazione diretta di Stephens a 19.567 azioni, un incremento di circa il 78% rispetto alla sua posizione precedente. Non sono stati esercitati o ceduti strumenti derivati, né sono state segnalate vendite o altre cessioni da parte di insider.

Pur non richiedendo un esborso diretto, la concessione rafforza modestamente l’allineamento azionario degli insider e invia un segnale generalmente positivo in termini di governance. L’importo complessivo è irrilevante rispetto alla capitalizzazione di CMCO, quindi si prevede un impatto limitato sul mercato.

Resumen del Formulario 4: El 21/07/2025, el director de Columbus McKinnon Corp. (CMCO), Christopher J. Stephens, reportó la adjudicación de 8,553 acciones ordinarias bajo el Plan de Incentivos a Largo Plazo Enmendado y Reformulado de 2016 de la compañía. La transacción está codificada como “A” (adquisición) a un precio de reporte de 15,21 $ por acción, lo que implica un valor nominal aproximado de 130.000 $.

La concesión eleva la participación directa de Stephens a 19.567 acciones, un aumento de alrededor del 78% respecto a su posición anterior. No se ejercieron ni se dispusieron valores derivados, y no se divulgaron ventas u otras disposiciones por parte de insiders.

Aunque las concesiones de acciones no implican una compra directa, la presentación fortalece modestamente la alineación accionarial de los insiders y envía una señal generalmente constructiva de gobernanza. El monto total es insignificante para la capitalización de CMCO, por lo que se espera que el impacto en el mercado sea limitado.

Form 4 요약: 2025년 7월 21일, Columbus McKinnon Corp.(CMCO) 이사인 Christopher J. Stephens가 회사의 2016년 제2차 수정 및 재작성 장기 인센티브 계획에 따라 8,553주 보통주 수여를 보고했습니다. 거래는 “A”(취득)로 분류되었으며, 보고 가격은 주당 15.21달러로, 명목 가치는 약 13만 달러에 해당합니다.

이번 수여로 Stephens의 직접 보유 주식이 19,567주로 증가했으며, 이전 보유량 대비 약 78% 증가한 수치입니다. 파생 증권의 행사나 처분은 없었고, 매도나 기타 내부자 처분도 보고되지 않았습니다.

주식 수여는 현금 지출을 수반하지 않지만, 이번 신고는 내부자의 지분 정렬을 다소 강화하며 대체로 긍정적인 거버넌스 신호를 보냅니다. 전체 금액은 CMCO 자본금에 비해 미미하여 시장 영향은 제한적일 것으로 예상됩니다.

Résumé du formulaire 4 : Le 21/07/2025, Christopher J. Stephens, administrateur de Columbus McKinnon Corp. (CMCO), a déclaré l’attribution de 8 553 actions ordinaires dans le cadre du Plan d’incitation à long terme modifié et reformulé de 2016 de la société. La transaction est codée « A » (acquisition) à un prix déclaré de 15,21 $ par action, ce qui implique une valeur notionnelle d’environ 130 000 $.

Cette attribution porte la détention directe de Stephens à 19 567 actions, soit une augmentation d’environ 78 % par rapport à sa position précédente. Aucun titre dérivé n’a été exercé ou cédé, et aucune vente ou autre cession d’initié n’a été divulguée.

Bien que les attributions d’actions ne nécessitent pas d’achat direct, ce dépôt renforce modestement l’alignement des intérêts des initiés et envoie un signal de gouvernance généralement positif. Le montant total est négligeable par rapport à la capitalisation de CMCO, donc l’impact sur le marché devrait être limité.

Formular 4 Zusammenfassung: Am 21.07.2025 meldete Christopher J. Stephens, Direktor von Columbus McKinnon Corp. (CMCO), die Zuteilung von 8.553 Stammaktien im Rahmen des Zweiten Geänderten und Neuformulierten Langfristigen Anreizplans 2016 des Unternehmens. Die Transaktion ist mit „A“ (Erwerb) codiert und erfolgte zu einem Berichtspreis von 15,21 $ pro Aktie, was einem nominellen Wert von etwa 130.000 $ entspricht.

Die Zuteilung erhöht Stephens’ direkten Bestand auf 19.567 Aktien, eine Steigerung von etwa 78 % gegenüber seiner vorherigen Position. Es wurden keine Derivate ausgeübt oder veräußert, und es gab keine Verkäufe oder sonstigen Insider-Transaktionen.

Obwohl Aktienzuteilungen keinen direkten Kauf erfordern, stärkt die Meldung die Insider-Aktienausrichtung leicht und sendet ein insgesamt positives Governance-Signal. Der Gesamtbetrag ist im Verhältnis zur Kapitalisierung von CMCO unerheblich, daher sollte der Markteinfluss begrenzt sein.

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

July 2025

 

Commission File Number 1-15182

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x                         Form 40-F   ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

 

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

 

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes  ¨                         No   x

 

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

 

 


 

EXHIBITS

 

Exhibit
Number

 

Description of Exhibits

 

 

 

99.1


Intimation dated July 23, 2025

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

DR. REDDY’S LABORATORIES LIMITED

(Registrant)

 

 

 

Date: July 23, 2025

By:

/s/ K Randhir Singh

 

 

Name: K Randhir Singh

 

 

Title:   Company Secretary

 

3

FAQ

How many CMCO shares did Director Christopher J. Stephens acquire?

He was awarded 8,553 common shares.

When did the share grant to Christopher Stephens occur?

The grant date reported is 07/21/2025.

What was the reported price of the CMCO shares granted?

The Form 4 lists a price of $15.21 per share for reporting purposes.

What is Christopher Stephens’ total CMCO holding after the transaction?

He now directly owns 19,567 shares.

Were any derivative securities reported in this Form 4?

No; the filing shows no derivative acquisitions or disposals.

Does this Form 4 indicate insider confidence in CMCO?

Equity grants increase insider exposure, so the event is generally viewed as mildly positive, though it was not an open-market purchase.
Dr Reddys Labs

NYSE:RDY

RDY Rankings

RDY Latest News

RDY Latest SEC Filings

RDY Stock Data

11.99B
832.13M
15.04%
2.19%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
India
Hyderabad